Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

QIAGEN Launches Novel Product Enabling Non-Invasive Prenatal Diagnostics And Cancer Detection
QIAGEN announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The new QIAamp Circulating Nucleic Acid Kit is expected to significantly facilitate the corresponding biomarker research and the introduction of novel molecular tests in prenatal diagnostics which can replace risky, invasive procedures such as amniocentesis.
generic viagra online
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food And Drug Administration Approval For KRYSTEXXA(TM) For Refractory Chronic Gout
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a vote of 14 to 1 that KRYSTEXXA(TM) (pegloticase), a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout. Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target Prescription Drug User Fee (PDUFA) action date for the FDA"s decision as to whether to grant marketing approval for KRYSTEXXA is August 1, 2009.
News of the day
Study Finds New Approach To Treating Heart Attacks Reduces Risk Of Life-Threatening Complications
Transferring heart attack patients to specialized hospitals to undergo angioplasty within six hours after receiving clot-busting drugs reduces the risk of life-threatening complications, according to a Canadian-led study published today. The findings, published in the New England Journal of Medicine, suggest that routine early transfer of patients after clot-busting drugs are administered results in significantly better outcomes than the current practice of transferring patients only when the clot-busting drugs fail.
Diagnostics

Swine Flu: NIAID Set To Launch Clinical Trials To Test 2009 H1N1 Influenza Vaccine Candidates

Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. "With the emergence of the 2009 H1N1 influenza virus, we have undertaken a collaborative and efficient process of vaccine development that is proceeding in stepwise fashion," says NIAID Director Anthony S. Fauci, M.D. After the isolation and characterization of the virus, the U. S. Centers for Disease Control and Prevention generated and distributed a 2009 H1N1 seed virus to vaccine manufacturers for the development of vaccine pilot lots for testing in clinical trials. "Now, NIAID will use our longstanding vaccine clinical trials infrastructure - the Vaccine and Treatment Evaluation Units - to help quickly evaluate these pilot lots to determine whether the vaccines are safe and to assess their ability to induce protective immune responses," says Dr. Fauci. "These data will be factored into the decision about how and if to implement a 2009 H1N1 flu immunization program this fall." Initial studies will look at whether one or two 15 microgram doses of H1N1 vaccine are needed to induce a potentially protective immune response in healthy adult volunteers (aged 18 to 64 years old) and elderly people (aged 65 and older). Researchers also will assess whether one or two 30 microgram doses are needed. The doses will be given 21 days apart, testing two manufacturers" vaccines (Sanofi Pasteur and CSL Biotherapies). If early information from those trials indicates that these vaccines are safe, similar trials in healthy children (aged 6 months to 17 years old) will begin. A concurrent set of trials will look at the safety and immune response in healthy adult and elderly volunteers who are given the seasonal flu vaccine along with a 15 microgram dose of 2009 H1N1 vaccine. The H1N1 vaccine would be given to different sets of volunteers either before, after, or at the same time as the seasonal flu vaccine. If early information from those studies indicates that these vaccines are safe, similar trials in healthy children (aged 6 months to 17 years old) will start. A panel of outside experts will conduct a close review of the safety data from these trials to spot any safety concerns in real time. Information from these studies in healthy people will help public health officials develop recommendations for immunization schedules, including the optimal dosage and number of doses for multiple age groups, including adults, the elderly, and children. Data may also be used to support decisions about the best recommendations for people in high risk groups, including pregnant women and people whose immune systems are weakened or otherwise compromised. The trials are being conducted in a compressed timeframe in a race against the possible autumn resurgence of 2009 H1N1 flu infections that may occur at the same time as seasonal influenza virus strains begin to circulate widely in the Northern Hemisphere. Close collaboration among NIAID, the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (a component of the Department of Health and Human Services) was key to launching the trials quickly while ensuring high standards. Following initial discussions between the agencies on trial design, NIAID prepared the protocols and submitted them to the FDA for review. FDA rapidly completed the necessary reviews and approved the trial protocols. Since 1962, NIAID"s Vaccine and Treatment Evaluation Units (VTEUs) have been intensively involved in the successful development and clinical testing of vaccines and treatments against many pathogens that threaten the health of people in the United States and around the world. Among the vaccines tested have been those that prevent seasonal influenza, H5N1 avian influenza and pneumococcal pneumonia. The VTEU network consists of eight university research hospitals and medical organizations across the United States that provide a ready re for conducting clinical trials that evaluate vaccines and treatments for a wide array of infectious diseases. An important strength of the VTEUs is their ability to rapidly enroll large numbers of volunteers into trials and to immunize the volunteers in a safe, effective and efficient manner. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns. Results are expected to be available weeks after the trials begin. NIAID"s Vaccine and Treatment Evaluation Units include the following: * Baylor College of Medicine, Houston * Children"s Hospital Medical Center, Cincinnati * Emory University, Atlanta * Group Health Cooperative, Seattle * Saint Louis University, St. Louis * University of Iowa, Iowa City * University of Maryland School of Medicine, Baltimore * Vanderbilt University, Nashville, Tenn. Further information about the five trials can be found at ClinicalTrials.gov at the following links: * 09-0053 Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Given at Two Dose Levels to Healthy Adult and Elderly Populations NCT00943631 (http://clinicaltrials.gov/show/NCT00943631) * 09-0043 Unadjuvanted CSL H1N1 Influenza Vaccine Given at Two Dose Levels to Healthy Adult and Elderly Populations NCT00943488 (http://clinicaltrials.gov/show/NCT00943488) * 09-0039 Licensed Seasonal Flu Vaccine Given Together or Sequentially with Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations NCT00943878 (http://clinicaltrials.gov/show/NCT00943878) * 09-0054 Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels to Children NCT00944073 (http://clinicaltrials.gov/show/NCT00944073) * 09-0047 Licensed Seasonal Flu Vaccine Given Together or Sequentially with Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Children NCT00943202 (http://clinicaltrials.gov/show/NCT00943202) Anne A. Oplinger NIH/National Institute of Allergy and Infectious Diseases


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009